CUSIP: 30049G302
Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1,552,381
-
Total 13F shares
-
590,713
-
Share change
-
+358,691
-
Total reported value
-
$2,937,342
-
Price per share
-
$4.97
-
Number of holders
-
15
-
Value change
-
+$1,814,237
-
Number of buys
-
11
-
Number of sells
-
3
Security key
30049G302
Report period
Q3 2025
Institutions
15
Top holders
10
Reporting periods
Holder history for CUSIP 30049G302
Recent filing periods:
Top shareholders of EVOK - Evoke Pharma Inc - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
No top shareholder records were found across 13F, 13D/G, and Forms 3/4/5 for this issuer.
Institutional Holders of Evoke Pharma Inc - Common Stock, par value $0.0001 per share (EVOK) as of Q3 2025
As of 30 Sep 2025,
Evoke Pharma Inc - Common Stock, par value $0.0001 per share (EVOK) was held by
15 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
590,713 shares.
The largest 10 holders included
MORGAN STANLEY, Nantahala Capital Management, LLC, Bleichroeder LP, National Wealth Management Group, LLC, DRW Securities, LLC, VANGUARD GROUP INC, TWO SIGMA SECURITIES, LLC, OSAIC HOLDINGS, INC., NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO, and ROYAL BANK OF CANADA.
This page lists
15
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
Compare Q3 2025 vs Q2 2025 Across Filers
| Investor |
Q2 2025 Shares |
Q3 2025 Shares |
Share Diff |
Share Chg % |
Q2 2025 Value $ |
Q3 2025 Value $ |
Value Diff $ |
Value Chg % |
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.